OR WAIT 15 SECS
Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.
Basel, Switzerland -Novartis plans to provide its malaria drug, Coartem (artemether/lumefantrin), at cost to developing countries in partnership with the World Health Organization (WHO). The effort is only the latest in a series of moves intended to increase access to essential medicines after Big Pharma’s South Africa debacle.